Added to YB: 2025-10-28
Pitch date: 2025-10-24
ALVO [bullish]
Alvotech
-34.39%
current return
Author Info
Ridire Research is an independent equity research platform focused on actionable, high-conviction long/short equity ideas. We combine fundamental rigor with quantitative structure to identify mispriced opportunities others overlook. Sign up for the newsletter.
Company Info
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
Market Cap
$1.8B
Pitch Price
$8.49
Price Target
N/A
Dividend
N/A
EV/EBITDA
51.08
P/E
23.31
EV/Sales
5.22
Sector
Biotechnology
Category
growth
Alvotech (ALVO): Biosimilar Foundry with Rare-Disease Reach
ALVO: Vertically integrated biosimilar manufacturer w/ end-to-end Iceland facility, regulatory moat across FDA/EMA/PMDA. Partner network (Teva US, STADA EU) creates distribution flywheel. Pipeline includes rare disease biosimilars (canakinumab, ofatumumab). Key risks: tender compression, regulatory reinspection, partner execution. Manufacturing-first moat vs discovery biotechs.
Read full article (3 min)